LEVETIRACETAM

PRODUCT IDENTIFICATION

CAS NO.

102767-28-2

LEVETIRACETAM 
EINECS NO.  
FORMULA C8H14N2O2
MOL WT. 170.21

TOXICITY

 

H.S. CODE

2933.99.9700
SYNONYMS

Levetiracetam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide;

(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (alphaS)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; Levetiracetamum; Keppra; (alphaS)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; 2(S)-(2-Oxopyrrolidin-1-yl)butyramide;

SMILES

N1([C@H](C(=O)N)CC)C(=O)CCC1

CLASSIFICATION

Antiepileptic,

EXTRA NOTES

 

PHYSICAL AND CHEMICAL PROPERTIES

PHYSICAL STATE white to off-white crystalline powder
MELTING POINT

118 ~ 119 C

BOILING POINT

 

SPECIFIC GRAVITY  
SOLUBILITY IN WATER

Insoluble

SOLVENT SOLUBILITY

 

pKa  
VAPOR DENSITY

 

log P

 

OH RATE CONSTANT  

REFRACTIVE INDEX

 

NFPA RATINGS

Health hazard: 2, Flammability: 0, Physical hazards: 0

AUTOIGNITION

 

FLASH POINT

 

STABILITY Stable under normal conditions.

EXTERNAL LINKS & GENERAL DESCRIPTION

Wikipedia Linking

Google Scholar Search

Drug Information Portal (U.S. National Library of Medicine) - Levetiracetam

PubChem Compound Summary - Levetiracetam

Drug Bank -  Levetiracetam

KEGG (Kyoto Encyclopedia of Genes and Genomes) -  Levetiracetam

http://www.ebi.ac.uk/ -  Levetiracetam

http://www.ncbi.nlm.nih.gov/ -  Levetiracetam

http://www.sigmaaldrich.com/
Biochem/physiol Actions: Levetiracetam is a pyrrolidine with antiepileptic activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.

http://www.ajhp.org/
Summary. Levetiracetam, an antiepileptic drug (AED), was first approved as an adjunctive therapy for the treatment of partial epilepsy in adults. It is currently being used in the treatment of multiple seizure disorders, including generalized tonic–clonic; absence; myoclonic, especially juvenile myoclonic; Lennox-Gastaut syndrome; and refractory epilepsy in children and adults. Data are emerging on possible uses of levetiracetam outside the realm of epilepsy because of its unique mechanisms of action. There is preliminary evidence about the efficacy of levetiracetam in the treatment of different psychiatric disorders, including anxiety, panic, stress, mood and bipolar, autism, and Tourette’s syndrome. The most serious adverse effects associated with levetiracetam use are behavioral in nature and might be more common in patients with a history of psychiatric and neurobehavioral problems. Conclusion. Levetiracetam is an effective AED with potential benefits in other neurologic and psychiatric disorders. The benefit–risk ratio in an individual patient with a specific condition should be used to determine its optimal use. Levetiracetam’s use in nonepileptic conditions is not recommended until more data become available from larger trials.

N03AX:

Product

CAS RN.

Sultiame

61-56-3

Phenacemide

63-98-9

Lamotrigine

84057-84-1

Felbamate

25451-15-4

Topiramate

97240-79-4

Gabapentin

60142-96-3

Pheneturide

90-49-3

Levetiracetam

102767-28-2

Zonisamide

68291-97-4

Pregabalin

148553-50-8

Stiripentol

49763-96-4

Lacosamide

175481-36-4

Carisbamate

194085-75-1

Retigabine

150812-12-7

Perampanel

380917-97-5

Beclamide

501-68-8
SALES SPECIFICATION

APPEARANCE

white to off-white crystalline powder

IDENTIFICATION

passes Test IR, HPLC

ASSAY

98.0 ~102.0%

SPECIFIC ROTATION

-89º ~ -91º

LOSS ON DRYING

0.5% max

R-FORM

0.5% max

HEAVY METALS

20ppm max

IMPURITY

1.0% max (total impurity), 0.4% max (Individual Impurity)

TRANSPORTATION
PACKING
 
HAZARD CLASS  
UN NO.

 

SAFETY INFORMATION

HAZARD OVERVIEW

Harmful by ingestion., Irritant

GHS

 

SIGNAL WORD

Warning

PICTOGRAMS

HAZARD STATEMENTS

H302-H319

P STATEMENTS

P305 + P351 + P338

PRICE INFORMATION